Last $0.85 USD
Change Today +0.02 / 2.41%
Volume 784.2K
PVCT On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 1:32 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

provectus biopharmaceutica-a (PVCT) Snapshot

Open
$0.83
Previous Close
$0.83
Day High
$0.87
Day Low
$0.79
52 Week High
05/16/14 - $3.75
52 Week Low
05/27/14 - $0.30
Market Cap
153.3M
Average Volume 10 Days
430.3K
EPS TTM
$-0.19
Shares Outstanding
180.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROVECTUS BIOPHARMACEUTICA-A (PVCT)

Related News

No related news articles were found.

provectus biopharmaceutica-a (PVCT) Related Businessweek News

No Related Businessweek News Found

provectus biopharmaceutica-a (PVCT) Details

Provectus Biopharmaceuticals, Inc., a development-stage biopharmaceutical company, is engaged in developing pharmaceuticals for oncology and dermatology indications. The company’s product line includes PV-10, which has completed Phase II study for metastatic melanoma; completed a Phase I study for breast cancer; and is in Phase I protocol expansion for liver metastasis, as well as initiated a Phase I feasibility study to detect immune cell infiltration into melanomas. It is also developing PH-10 that is in Phase IIc randomized study for the treatment of psoriasis; and has completed Phase II study for the treatment of atopic dermatitis. In addition, the company develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris. Further, it is developing over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products. Additionally, Provectus Biopharmaceuticals, Inc. develops medical device technologies for markets comprising cosmetic treatments, such as reduction of wrinkles and elimination of spider veins, and other cosmetic blemishes; and therapeutic uses, including photoactivation of PH-10, other prescription drugs, and non-surgical destruction of certain skin cancers. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

4 Employees
Last Reported Date: 11/6/14
Founded in 2002

provectus biopharmaceutica-a (PVCT) Top Compensated Officers

Chairman, Chief Executive Officer, Chief Exec...
Total Annual Compensation: $500.0K
President, Director, President of Xantech and...
Total Annual Compensation: $500.0K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $500.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2013.

provectus biopharmaceutica-a (PVCT) Key Developments

Provectus Biopharmaceuticals, Inc. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015

Provectus Biopharmaceuticals, Inc. Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 through Mar-04-2015. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Presentation Date & Speakers: Mar-03-2015, Peter R. Culpepper, Chief Operating Officer, Chief Financial Officer, Chief Accounting Officer, Corporate Treasurer and Secretary.

Provectus Biopharmaceuticals Held Type C Meeting with Food and Drug Administration on Operational Aspects of PV-10 Phase 3 Melanoma Study

Provectus Biopharmaceuticals, Inc. announced that it has held a Type C meeting with the U.S. Food and Drug Administration to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma. The meeting was held by teleconference on January 29, 2015. Topics formally reviewed included subject eligibility requirements, primary and secondary study end points, and study lesion definitions and conventions for defining disease progression.

Provectus Biopharmaceuticals, Inc.’ Protocol for Phase 2 Study of Mechanism of Action of PH-10 on Immunologic Makers of Psoriasis Now Available Online

Provectus Biopharmaceuticals, Inc. announced that the protocol for its phase 2 study of the mechanism of action of PH-10 in psoriasis is now available on ClinicalTrials.gov [2], Identifier NCT02322086. The protocol states that the multicenter study is designed to assess treated psoriatic plaque for “changes in immunologic, structural and hyperproliferative state and for any evidence of cellular atypia” when treated with PH-10 and to “correlate observed changes in the skin with clinical response to treatment.” These assessments are expected to advance the understanding of the mechanism of action of PH-10 in psoriasis and other inflammatory dermatoses, such as atopic dermatitis, and further substantiate the safety profile of the agent. The study will enroll up to 30 subjects with mild to moderate plaque psoriasis. Subjects will apply vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their psoriatic plaques. Biopsies of one plaque will be collected at baseline and immediately after completion of vehicle application and PH-10 application. This will allow data from each subject to serve as an internal control for assessment of clinical and cellular response to PH-10. Biopsy specimens will be assessed for changes in epidermal hyperplasia (i.e., disordered condition of the skin creating thickening and scaling); infiltration with immune cells; and molecular markers of inflammation. Correlation of clinical response to these cellular and molecular changes will be performed at the plaque level using Psoriasis Severity Index (PSI) assessment data. Safety will be assessed by monitoring the frequency, duration, severity and attribution of clinical adverse events; evaluating changes in laboratory values and vital signs; and by correlation of clinical adverse events with observed histopathologic and immunohistopathologic changes in the skin.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PVCT:US $0.85 USD +0.02

PVCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PVCT.
View Industry Companies
 

Industry Analysis

PVCT

Industry Average

Valuation PVCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROVECTUS BIOPHARMACEUTICA-A, please visit www.pvct.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.